Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 60% of modeled bridge. Strengths: Bed Count, Commercial Payer %. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $0.3M (vs $0.5M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $199K | $8K | $207K | $0 | 12mo |
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $206K | $206K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $32K | $94K | $126K | $396K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 64.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | $0 | $52K | $103K | $155K | $207K | $207K | $207K | $207K |
| Cost to Collect | $0 | $52K | $103K | $155K | $206K | $206K | $206K | $206K |
| A/R Days Reduction | $0 | $42K | $84K | $126K | $126K | $126K | $126K | $126K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $150K | $300K | $445K | $548K | $548K | $548K | $548K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $548K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 81% / 19.4x | 86% / 22.0x | 90% / 24.5x | 92% / 25.8x | 93% / 27.0x |
| 9.0x | 76% / 16.9x | 81% / 19.2x | 85% / 21.4x | 86% / 22.5x | 88% / 23.7x |
| 10.0x | 72% / 14.9x | 76% / 16.9x | 80% / 18.9x | 82% / 20.0x | 84% / 21.0x |
| 11.0x | 68% / 13.3x | 72% / 15.1x | 76% / 16.9x | 78% / 17.9x | 80% / 18.8x |
| 12.0x | 64% / 11.9x | 68% / 13.6x | 72% / 15.2x | 74% / 16.1x | 76% / 16.9x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 56% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.9x, adding 5.6 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $282K | — | $282K | 2.7% |
| Year 1 | $290K | +$365K | $656K | 6.4% |
| Year 2 | $299K | +$548K | $847K | 8.2% |
| Year 3 | $308K | +$548K | $856K | 8.3% |
| Year 4 | $317K | +$548K | $865K | 8.4% |
| Year 5 | $327K | +$548K | $875K | 8.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Denial Rate Reductio | $103K | $155K | $207K | $248K |
| Cost to Collect | $103K | $155K | $206K | $248K |
| A/R Days Reduction | $63K | $94K | $126K | $151K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $274K | $411K | $548K | $658K |
Peer Context — Where This Hospital Sits
Key metrics vs 87 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.7% | -12.6% | -3.0% | 3.0% | P72 |
| Net-to-Gross | 72.1% | 52.1% | 59.5% | 64.2% | P89 |
| Occupancy | 16.1% | 15.6% | 30.7% | 41.6% | P29 |
| Rev/Bed | $688K | $1.1M | $1.8M | $2.7M | P10 |
| Exp/Bed | $669K | $993K | $1.7M | $2.7M | P14 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.